

A Case Report on the Management of Schizophrenia with Antipsychotic Medications

Vipul Singh*

Department of Psychology, Dr Bhim Rao Ambedkar College, University of Delhi, New Delhi, India

Abstract

This case report describes the experience of a patient diagnosed with schizophrenia who underwent treatment with antipsychotic medications. It highlights the challenges faced during treatment and emphasizes the importance of patient-psychiatrist communication and the journey toward recovery. The report underscores the need for personalized treatment approaches in managing mental health conditions.

Keywords: Schizophrenia • Antipsychotics • Patient experience • Case report • Mental health

Introduction

Schizophrenia is a chronic mental health disorder characterized by symptoms such as hallucinations, delusions, and cognitive impairment. Antipsychotic medications are the primary treatment modality, and their effectiveness can vary among patients. This case report aims to illustrate the treatment journey of a patient with schizophrenia and the implications for patient-psychiatrist communication and treatment personalization.

Case Presentation

Patient information

Age: 18

Gender: Male

Diagnosis: Schizophrenia

Initial presentation

The patient was diagnosed with schizophrenia at the age of 14. Initial symptoms included auditory hallucinations, visual hallucinations, and social withdrawal.

Treatment history

Upon diagnosis, the patient was prescribed atypical antipsychotic medications Olanzapine and Aripiprazole. The patient experienced some initial improvement in symptoms, which led to a positive outlook on treatment.

Progression and recovery

After a period of consistent treatment, including medication adherence and regular follow-ups with the healthcare provider, the patient reported significant improvements in overall mental health. They experienced reduced symptoms of schizophrenia and began to reintegrate into daily life activities.

***Address for Correspondence:** Vipul Singh, Department of Psychology, Dr Bhim Rao Ambedkar College, University of Delhi, New Delhi, India, Tel: 9718757337, E-mail: vipul190506@gmail.com

Copyright: © 2024 Singh V. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Received: 25 October 2024, Manuscript No. jccr-24-150967; **Editor assigned:** 28 October 2024, PreQC No. P-150967; **Reviewed:** 08 November 2024, QC No. Q-150967; **Revised:** 15 November 2024, Manuscript No. R-150967; **Published:** 22 November 2024, DOI: 10.37421/2165-7920.2024.14.1628

This recovery process included participation in therapy sessions and support groups, which contributed to personal growth and resilience [1].

Discussion

This case illustrates the positive outcomes that can arise from effective management of schizophrenia with antipsychotic medications. The patient's journey highlights the critical role of effective communication between patients and healthcare providers in fostering a supportive treatment environment [2,3].

Engaging in open dialogue about treatment goals and recovery can significantly enhance patient adherence and satisfaction. Research indicates that comprehensive treatment approaches, which include medication, therapy, and peer support, can lead to better recovery outcomes [4,5].

Conclusion

This case report emphasizes the importance of personalized treatment approaches in managing schizophrenia. By sharing this patient's recovery journey, the report aims to encourage healthcare providers to prioritize open communication and collaboration with patients. Future studies should focus on strategies to enhance patient-provider interactions and improve mental health outcomes.

Acknowledgement

None.

Conflict of Interest

None.

References

- Leucht, Stefan, Andrea Cipriani, Loukia Spineli and Dimitris Mavridis, et al. "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis." *Lancet* 382 (2013): 951-962.
- Kane, John M., Taishiro Kishimoto and Christoph U. Correll. "Non-adherence to medication in patients with psychotic disorders: Epidemiology, contributing factors and management strategies." *World Psychiatry* 12 (2013): 216-226.
- Tiihonen, Jari, Ellenor Mittendorfer-Rutz, Maila Majak and Juha Mehtälä, et al. "Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia." *JAMA Psychiatry* 74 (2017): 686-693.

4. Buchanan, Robert W., Julie Kreyenbuhl, Deanna L. Kelly and Jason M. Noel, et al. "The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements." *Schizophra Bull* 36 (2010): 71-93.
5. Howes, Oliver D. and Shitij Kapur. "The dopamine hypothesis of schizophrenia: Version III—the final common pathway." *Schizophr Bull* 3 (2009): 549-562.

How to cite this article: Singh, Vipul. "A Case Report on the Management of Schizophrenia with Antipsychotic Medications." *J Clin Case Rep* 14 (2024): 1628